Corticosteroids in the management of early and established rheumatoid disease

Rheumatology

Volumn 45, Issue 9, 2006, Pages 1058-1061

  Morrison, Elaine ^a   Capell, H A ^b  

^a SOUTHERN GENERAL HOSPITAL   (United Kingdom)

^b GLASGOW ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AUROTHIOMALATE; CORTICOSTEROID DERIVATIVE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GOLD COMPLEX; INFLIXIMAB; METHOTREXATE; METHYLPREDNISOLONE; METHYLPREDNISOLONE ACETATE; PENICILLAMINE; PLACEBO; PREDNISOLONE; PREDNISONE; SALAZOSULFAPYRIDINE; TRIAMCINOLONE; TUMOR NECROSIS FACTOR ALPHA;

ADDISON DISEASE; BODY WEIGHT DISORDER; CARDIOVASCULAR RISK; CATARACT; CLINICAL ASSESSMENT; CLINICAL TRIAL; CORTICOSTEROID INDUCED OSTEOPOROSIS; DIABETES MELLITUS; DISEASE EXACERBATION; DRUG EFFICACY; EDITORIAL; FACE EDEMA; GLAUCOMA; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERTENSION; INFECTION; LIPODYSTROPHY; MANAGED CARE; MOOD DISORDER; PRESCRIPTION; PRIORITY JOURNAL; RADIODIAGNOSIS; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SKIN BRUISING; SKIN DISEASE; VERTEBRA FRACTURE;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; GLUCOCORTICOIDS; HUMANS; PATIENT SELECTION; RISK; TREATMENT OUTCOME;

EID: 33749645143     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kel230     Document Type: Editorial

References (33)

1. Grigor C, Capell H, Stirling A et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): A single-blind randomised controlled trial. Lancet 2004;364:263-9.
2. Goekoop-Ruiterman YPM, de Vries-Bouwstra JK, Allaart CF et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt Study). A randomised controlled trial. Arthritis Rheum 2005; 52:3381-90.
3. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000;342:836-43.
4. Wallberg-Jonsson S, Johanson H, Ohman ML, Rantapaa-Dahlqvist S. Extent of inflammation predicts cardiovascular disease and overall mortality in seropositive rheumatoid arthritis. A retrospective cohort study from disease onset. J Rheumatol 1999;26:2562-71.
5. Hall FC, Dalbeth N. Disease modification and cardiovascular risk reduction: Two sides of the same coin? Rheumatology 2005; 44:1473-82.
6. Morrison E, Crosbie D, Capell HA. Attitude of rheumatoid arthritis patients to treatment with oral corticosteroids. Rheumatology 2003; 42:1247-50.
7. Morrison E, Capell HA. Corticosteroids in the management of rheumatoid arthritis. Br J Rheumatol 1996;35:2-4.
8. Morrison E, Capell HA. Corticosteroids in rheumatoid arthritis - the case against. Rheumatology 1999;38:97-100.
9. Kirwan J, and the Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group. The effect of glucocorticoids on joint destruction in rheumatoid arthritis. N Engl J Med 1995;333:142-6.
10. Boers M, Verhoven AC, Markusse HM et al. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 1997;350:309-18.
11. van Everdingen AA, Jacobs JW, Siewertsz van Reesma DR, Bijlsma JW. Low-dose prednisolone therapy for patients with early active rheumatoid arthritis: Clinical efficacy, disease-modifying properties, and side-effects: A randomised, double-blind, placebo-controlled clinical trial. Ann Intern Med 2002;136:1-12.
12. Capell HA, Madhok R, Hunter JA et al. Lack of radiological and clinical benefit over two years of low dose prednisolone for rheumatoid arthritis: Results of a randomised controlled trial. Ann Rheum Dis 2004;63:797-803.
13. Wassenberg S, Rau R, Steinfeld P, Zeidler H, for the Low-dose Prednisolone Therapy Study Group. Very low-dose prednisolone in early rheumatoid arthritis retards radiographic progression over two years. A multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 2005;52:3371-80.
14. Svensson B, Boonen A, Albertsson K, van der Heijde, Kellar C, Hafström I, for the BARFOT Study Group. Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate. A two year randomised trial. Arthritis Rheum 2005;52:3360-70.
15. Hickling P, Jacoby RK, Kirwan JR. and the Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group. Joint destruction after glucocorticoids are withdrawn in early rheumatoid arthritis. Br J Rheumatol 1998;37:930-6.
16. Taves DR. Minimisation: A new method of assigning patients to treatment and control groups. Clin Pharmacol Ther 1974;15:443-53.
17. Treasure T, MacRae KD. Minimisation: The platinum standard for trials? Randomisation doesn't guarantee similarity of groups; minimisation does (Editorial). Br Med J 1998;317:362-3.
18. Hench PS, Kendall EC, Slocumb CH, Polley HF. The effect of a hormone of the adrenal cortex (17-hydroxy-11-dehydrocortisone: Compound E) and of pituitary adrenocorticotrophic hormone on rheumatoid arthritis. Preliminary report. Proc Staff Meet Mayo Clin 1949;24:181-97.
19. Empire Rheumatism Council. Multi-centre controlled trial comparing cortisone acetate and acetyl salicylic acid in the long-term treatment of rheumatoid arthritis. Results of three years treatment. Ann Rheum Dis 1957;16:277-89.
20. Da Silva JAP, Jacobs JWG, Kirwan JR et al. Safety of low dose glucocorticoid treatment in rheumatoid arthritis: Published evidence and prospective trial data. Ann Rheum Dis 2006;65:285-93.
21. Caplan L, Russell AS, Wolf F. Steroids for Rheumatoid Arthritis: The honeymoon revisited (once again). J Rheumatol 2005;32:1863-5.
22. Harris ED. Prednisolone in Early Rheumatoid Arthritis: An antiinvasive Effect. Arthritis Rheum 2005;52:3324-5.
23. Hansen TM, Dickmeiss E, Jans H, Hansen TI, Ingeman-Nielsen M, Lorenzen IB. Combination of methylprednisolone pulse therapy and remission inducing drugs in rheumatoid arthritis. Annals Rheum Dis 1987;46:290-5.
24. Corkill MM, Kirkham BW, Chikanza C, Gibson T, Panayi G. Intramuscular depot methylprednisolone induction of chrysotherapy in rheumatoid arthritis: A 24 week randomised controlled trial. Br J Rheumatol 1990;29:274-9.
25. Hansen TM, Kryger P, Elling H et al. Double blind placebo controlled trial of pulse treatment with methylprednisolone combined with disease modifying drugs in rheumatoid arthritis. Br Med J 1990;301:268-70.
26. Van Gestel AM, Laan RFJM, Haagsma CJ, Van de Putte LBA, Van Riel PLCM. Oral steroids as bridge therapy in rheumatoid arthritis patients starting with parenteral gold. A randomised double-blind placebo-controlled trial. Br J Rheumatol 1995;34:347-51.
27. Ciconelli RM, Ferraz MB, Visioni RA, Oliveira LM, Atra E. A randomised double-blind controlled trial of sulphasalazine combined with pulses of methylprednisolone or placebo in the treatment of rheumatoid arthritis. Br J Rheumatol 1996;35:150-4.
28. Saag KG, Koehke R, Caldwell JR et al. Low dose long-term corticosteroid therapy in rheumatoid arthritis: An analysis of serious adverse events. American J Med 1994;96:115-23.
29. Choy EH, Kingsley GH, Khoshaba B, Pipitone N, Scott DL, the Intramuscular Methylprednisolone Study Group. A two year randomised controlled trial of intramuscular depot steroids in patients with established rheumatoid arthritis who have shown an incomplete response to disease modifying antirheumatic drugs. Ann Rheum Dis 2005;64:1288-93.
30. Durez P, Nzeusseu Toukap A, Lauwerys BR et al. A randomised comparative study of the short term clinical and biological benefits of intravenous pulse methylprednisolone and infliximab in patients with active rheumatoid arthritis despite methotrexate treatment. Ann Rheum Dis 2004;63:1069-74.
31. Furtado RNV, Olivera LM, Natour J. Polyarticular corticosteroid injection versus systemic administration in treatment of rheumatoid arthritis patients: A randomised controlled study. J Rheumatol 2005; 32:1691-8.
32. Davis JM, Maradit-Kremers H, Gabriel SE. Use of low-dose glucocorticoids and the risk of cardiovascular morbidity and mortality in rheumatoid arthritis: What is the true direction of the effect? J Rheumatol 2005;32:1856-62.
33. del Rincón I, Williams K, Stern MP, Freeman GL, Escalante A. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 2001;44:2737-45.